share_log

Alzamend Neuro | 10-K: FY2024 Annual Report

Alzamend Neuro | 10-K: FY2024 Annual Report

Alzamend Neuro | 10-K：2024財年年報
美股SEC公告 ·  2024/07/31 10:20

Moomoo AI 已提取核心訊息

Alzamend Neuro reported a net loss of $9.9 million for fiscal year 2024, compared to $14.9 million in FY2023. Operating expenses decreased to $9.9 million from $14.9 million, with research and development costs at $6.5 million and general and administrative expenses at $3.5 million. The company ended the year with $376,000 in cash.The company made significant progress in its clinical programs during FY2024. For AL001, Alzamend successfully identified a maximum tolerated dose in Phase IIA trials and received FDA "study may proceed" letters for additional indications including bipolar disorder, major depressive disorder, and PTSD. The company also initiated a Phase I/IIA clinical trial for ALZN002 to treat mild to moderate dementia of Alzheimer's type.To strengthen its financial position, Alzamend secured new funding through Series B Preferred Stock sales to Ault Lending totaling $2.1 million and raised $1.3 million through an at-the-market offering. Post fiscal year-end, the company entered into agreements with Orchid Finance for up to $25 million in Series A Preferred Stock financing to advance its clinical programs.
Alzamend Neuro reported a net loss of $9.9 million for fiscal year 2024, compared to $14.9 million in FY2023. Operating expenses decreased to $9.9 million from $14.9 million, with research and development costs at $6.5 million and general and administrative expenses at $3.5 million. The company ended the year with $376,000 in cash.The company made significant progress in its clinical programs during FY2024. For AL001, Alzamend successfully identified a maximum tolerated dose in Phase IIA trials and received FDA "study may proceed" letters for additional indications including bipolar disorder, major depressive disorder, and PTSD. The company also initiated a Phase I/IIA clinical trial for ALZN002 to treat mild to moderate dementia of Alzheimer's type.To strengthen its financial position, Alzamend secured new funding through Series B Preferred Stock sales to Ault Lending totaling $2.1 million and raised $1.3 million through an at-the-market offering. Post fiscal year-end, the company entered into agreements with Orchid Finance for up to $25 million in Series A Preferred Stock financing to advance its clinical programs.
Alzamend Neuro報告2024財政年度淨虧損990萬美元，相較於2023財政年度的1490萬美元。營業費用從1490萬美元減少到990萬美元，研究與開發費用爲650萬美元，管理費用爲350萬美元。公司年末現金餘額爲376,000美元。在2024財政年度，公司的臨牀項目取得了重大進展。在AL001方面，Alzamend在IIA階段試驗中成功確定了最大耐受劑量，並收到了FDA的「研究可以繼續」信件，涉及雙相障礙、重度抑鬱障礙和創傷後應激障礙的額外適應症。公司還啓動了針對老年癡呆類型輕度至中度癡呆症的ALZN002 I/IIA期臨牀試驗。爲了增強財務狀況，Alzamend通過向Ault Lending銷售210萬美元的B系列優先股獲得了新資金，並通過市場掛牌募資130萬美元。在財政年度結束後，公司與蘭花協議簽署了高達2500萬美元的A系列優先股融資協議，以推進其臨牀項目。
Alzamend Neuro報告2024財政年度淨虧損990萬美元，相較於2023財政年度的1490萬美元。營業費用從1490萬美元減少到990萬美元，研究與開發費用爲650萬美元，管理費用爲350萬美元。公司年末現金餘額爲376,000美元。在2024財政年度，公司的臨牀項目取得了重大進展。在AL001方面，Alzamend在IIA階段試驗中成功確定了最大耐受劑量，並收到了FDA的「研究可以繼續」信件，涉及雙相障礙、重度抑鬱障礙和創傷後應激障礙的額外適應症。公司還啓動了針對老年癡呆類型輕度至中度癡呆症的ALZN002 I/IIA期臨牀試驗。爲了增強財務狀況，Alzamend通過向Ault Lending銷售210萬美元的B系列優先股獲得了新資金，並通過市場掛牌募資130萬美元。在財政年度結束後，公司與蘭花協議簽署了高達2500萬美元的A系列優先股融資協議，以推進其臨牀項目。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Portage Biotech
    PRTG
    -- 9.600
    萊斯康製藥
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日